

FOURTH QUARTER 2018

HIGHLIGHTS

- Revenue for the quarter was USD 35.5 million, up from USD 34.2 million in fourth quarter last year. Revenue for the full year was USD 155.3 million compared to USD 125.5 million in 2017.
- EBITDA for the quarter was USD 1.7 million, up from USD 0.5 million one year earlier. Full year EBITDA was USD 33.1 million, up from USD 17.2 million in 2017.
- Solid offshore performance with 3 900 MT krill meal produced in the quarter compared to 3 580 MT in the same period last year.
- Total equity at the end of the year was USD 178.8 million.


EVENTS AND OUTLOOK

- New krill vessel *Antarctic Endurance* delivered in January 2019. Expected to start commercial harvest in Q2 2019.
- Contract signed with yard in China to build a new support vessel.
- Well executed capacity increase project at the krill oil factory in Houston enabling increased future production of Superba™ krill oil.
- The market for omega-3 products, which is the key market for Superba™ krill oil, maintains an optimistic outlook. The outlook for the market for krill derived product remains positive.

KEY FIGURES


REVENUES

USD million




EBITDA

USD million



KRILL MEAL PRODUCTION

MT



Consolidated financial information - key figures

Aker BioMarine (AKBM) is an integrated biotechnology group that harvests, processes, markets, and sell krill-derived ingredients for health and nutrition applications ranging from fish feed to dietary supplements.

Amounts in thousands of U.S. Dollars	Q4 - 18	Q4 - 17	YTD - 18	YTD - 17
Revenues from sale of products	35 767	33 847	154 182	124 154
Other income	(213)	368	1 152	1 386
Total revenues and other income	35 554	34 215	155 334	125 540
Production and misc. operating expenses	(23 362)	(24 700)	(82 202)	(75 395)
Salaries and payroll expenses	(10 499)	(8 969)	(40 014)	(32 931)
Total operating expenses before depreciation, amortization and impairment	(33 862)	(33 669)	(122 216)	(108 326)
Depreciation and amortization	(6 919)	(6 877)	(21 960)	(18 896)
Impairment charges and gain(loss) from sale of fixed assets	(900)	-	(900)	-
Operating profit (loss)	(6 127)	(6 331)	10 258	(1 682)
Net financial expenses	302	(4 045)	(11 541)	(15 072)
Net profit (loss) before tax expense	(5 825)	(10 376)	(1 283)	(16 754)
Tax expense	(60)	(430)	259	(1 011)
Net profit (loss)	(5 885)	(10 806)	(1 024)	(17 765)
Other comprehensive income				
Defined benefit plan actuarial gains (losses)	119	(118)	119	(118)
Translation	(14)	-	(14)	-
Cash flow hedges gains (losses)	(3 901)	(2 566)	(4 625)	3 153
Total other comprehensive income	(3 796)	(2 684)	(4 520)	3 035
			-	
Total comprehensive income (loss)	(9 681)	(13 490)	(5 544)	(14 730)

EBITDA for the quarter was USD 1.7 million, up from USD 0.5 million a year earlier primarily reflecting improved product margins.

Revenue and other income

Sale of products generated USD 35.8 million in revenues in the fourth quarter, up from USD 33.8 million last year. The increase is primarily explained by a combination of organic and acquired growth in the krill oil segment as well as additional Qrill Aqua volume sold in the quarter.

Operating expenses

Production, operating expenses and change in inventories

Production and operating expenses were USD 23.4 million in the fourth quarter, compared with USD 24.7 million last year. The decrease in production and operating expenses reflects certain one-off effects in 2017 combined with lower cost of goods sold in 2018, despite higher production costs due to build-up of Qrill Aqua inventories.

Net financial expenses

Net financial items include interest expense on debt facilities, unrealized losses on NOK denominated debt, and the guarantee fee to Aker ASA. In the fourth quarter financial expenses was offset by foreign exchange gain on NOK denominated debt.

CONDENSED BALANCE SHEET AND KEY FIGURES

Amounts in thousands of U.S. Dollars	2018	2017
Total assets	430 242	377 413
Total equity	178 814	59 297
Net interest bearing debt	202 853	272 552
Net working capital	50 514	41 157
Equity ratio	42 %	16 %

Total assets

Total assets have significantly increased since year-end 2017. The increase reflects the acquisition of Enzymotec's krill business, the acquisition of krill-oil extraction technology as well as general investments to increase the krill oil production capacity in Houston.

Net interest bearing debt

Net interest-bearing debt (interest-bearing loans less cash and cash equivalents) amounted to USD 202.8 million at the end of the quarter, down from USD 272.6 million at year-end 2017. The decrease primarily relates to debt conversion of USD 125.1 million of the revolving credit facility provided by Aker ASA, offset by new loans incurred in 2018 due to the Enzymotec acquisition and working capital funding while constructing the new vessel.

Net working capital

At quarter end, net working capital (non-interest-bearing current assets less non-interest-bearing current debt) exclusive of bank deposits was USD 50.5 million, up from USD 41.2 million at year-end 2017. The increase mainly reflects an increase in customer receivables and inventory in addition to a decrease in payables.

Alternative Performance Measures

EBITDA: Operating profit (loss) + depreciation, amortization and impairment charges